Operating income decreased 38.6%
Operating income changed -38.6% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating income changed -38.6% from the comparable as-filed period.
Research & development changed +150.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Net income changed -41.6% from the comparable as-filed period.
Gross margin changed +551 basis points from the comparable as-filed period.
Operating margin changed -1618347 basis points from the comparable as-filed period.
Revenue changed -82.8% from the comparable as-filed period.
Cash & equivalents changed +133.0% from the comparable as-filed period.
Gross profit changed -81.4% from the comparable as-filed period.
Inventory changed +35.0% from the comparable as-filed period.
Inventory / revenue changed +167471 basis points from the comparable as-filed period.
Selling, general & administrative changed -12.4% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.